Intellia Therapeutics, Inc.
LSE: 0JBU.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- John Leonard
- Employees
- 403
- Headquarters
- Cambridge, United States
- IPO year
- 2018
- Market cap
- $1.5B
- Website
- https://www.intelliatx.com
Loading 0JBU…
Loading profile data…Frequently asked questions about 0JBU
What does Intellia Therapeutics, Inc. (0JBU.L) do?
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
Where does 0JBU.L trade?
Intellia Therapeutics, Inc. (0JBU.L) trades on the London Stock Exchange.
What sector is 0JBU.L in?
Intellia Therapeutics, Inc. (0JBU.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Intellia Therapeutics, Inc.?
John Leonard is the chief executive officer of Intellia Therapeutics, Inc. (0JBU.L).
Where is Intellia Therapeutics, Inc. headquartered?
Intellia Therapeutics, Inc. is headquartered in United States.
Does 0JBU.L pay a dividend?
Intellia Therapeutics, Inc. (0JBU.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0JBU.L go public?
Intellia Therapeutics, Inc. (0JBU.L) completed its initial public offering in 2018.